Nora Rosenberg

Associate Professor, Research Director

University of North Carolina at Chapel Hill
Country flagUnited States

Research Interests

Explore related searches

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Nora Rosenberg is an Associate Professor and Research Director at the University of North Carolina at Chapel Hill, USA. Her research primarily focuses on HIV prevention and treatment strategies, particularly among vulnerable populations in sub-Saharan Africa. Recent articles authored by Dr. Rosenberg explore topics such as couple-based interventions for HIV, risk assessment tools for women, and innovative approaches to HIV testing and counselling.

Articles (7)

Year:

2025

Background Women in Africa disproportionately acquire HIV-1. Understanding which women are most likely to acquire HIV-1 can guide focused prevention with pre-exposure prophylaxis (PrEP). Our objective is to identify women at highest risk of HIV-1 and estimate PrEP efficiency at different sensitivity levels. Methods Nationally representative data were collected from 2015-2019 from 15 population-based household surveys. This analysis included women aged 15-49 who tested HIV-1 sero-negative or had recent HIV-1. Least absolute shrinkage and selection operator regression models were fit with 28 variables to predict recent HIV-1. Models were trained on the full population and internally cross-validated. Performance was evaluated using area under the receiver-operating-characteristic curve (AUC), sensitivity, and number needed to treat (NNT) with PrEP to avert one infection. Results Among 209,012 participants 248 had recent HIV-1 infection, representing 118 million women and 402,000 (95% CI: 309,000-495,000) new annual infections. Two variables were retained in the model: living in a subnational area with high HIV-1 viremia and having a sexual partner living outside the home. Full-population AUC was 0.80 (95% CI: 0.76-0.84); cross-validated AUC was 0.79 (95% CI: 0.75-0.84). At a sensitivity of 33%, up to 130,000 cases could be averted if 7.9 million women were perfectly adherent to PrEP; NNT would be 61. At a sensitivity of 67%, up to 260,000 cases could be averted if 25.1 million women were perfectly adherent to PrEP; the NNT would be 96. Conclusions This risk assessment tool was generalizable, predictive, and parsimonious with tradeoffs between reach and efficiency.

Year:

2024

Year:

2023

Year:

2023

Year:

2022

Year:

2020

Year:

2020

Collaborators (3)

Benjamin H Chi

University of North Carolina at Chapel Hill

UNITED STATES
View details

Nuala McGrath

University of Southampton

UNITED KINGDOM
View details

Katherine Simon

Assistant Professor

Baylor College of Medicine

UNITED STATES
View details
ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.